US20170049716A1 - Nitisinone dosing regimens for the treatment of alkaptonuria - Google Patents
Nitisinone dosing regimens for the treatment of alkaptonuria Download PDFInfo
- Publication number
- US20170049716A1 US20170049716A1 US15/307,622 US201515307622A US2017049716A1 US 20170049716 A1 US20170049716 A1 US 20170049716A1 US 201515307622 A US201515307622 A US 201515307622A US 2017049716 A1 US2017049716 A1 US 2017049716A1
- Authority
- US
- United States
- Prior art keywords
- nitisinone
- administered
- dose
- hga
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OUBCNLGXQFSTLU-UHFFFAOYSA-N nitisinone Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1C(=O)C1C(=O)CCCC1=O OUBCNLGXQFSTLU-UHFFFAOYSA-N 0.000 title claims abstract description 113
- 229960001721 nitisinone Drugs 0.000 title claims abstract description 111
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 206010001689 alkaptonuria Diseases 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- IGMNYECMUMZDDF-UHFFFAOYSA-N homogentisic acid Chemical compound OC(=O)CC1=CC(O)=CC=C1O IGMNYECMUMZDDF-UHFFFAOYSA-N 0.000 description 90
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 42
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 42
- 210000002966 serum Anatomy 0.000 description 39
- 230000036325 urinary excretion Effects 0.000 description 18
- 230000007423 decrease Effects 0.000 description 11
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- GACSIVHAIFQKTC-OWOJBTEDSA-N 4-fumarylacetoacetic acid Chemical compound OC(=O)CC(=O)CC(=O)\C=C\C(O)=O GACSIVHAIFQKTC-OWOJBTEDSA-N 0.000 description 4
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 4
- GACSIVHAIFQKTC-UPHRSURJSA-N 4-maleylacetoacetic acid Chemical compound OC(=O)CC(=O)CC(=O)\C=C/C(O)=O GACSIVHAIFQKTC-UPHRSURJSA-N 0.000 description 4
- 102000030513 Homogentisate 1,2-Dioxygenase Human genes 0.000 description 4
- 108700023439 Homogentisate 1,2-dioxygenases Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- 102100028626 4-hydroxyphenylpyruvate dioxygenase Human genes 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- RAPRJRLALQKSHB-UHFFFAOYSA-N benzoquinoneacetic acid Chemical compound OC(=O)CC1=CC(=O)C=CC1=O RAPRJRLALQKSHB-UHFFFAOYSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010056476 Corneal irritation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- FRUDQMSGWOBWDY-BKSNUZHZSA-H NC(CC1=CC=C(O)C=C1)C(=O)O.NC(CC1=CC=CC=C1)C(=O)O.O=C([O-])/C=C/C(=O)CC(=O)CC(=O)O.O=C([O-])/C=C/C(=O)[O-].O=C([O-])/C=C\C(=O)CC(=O)CC(=O)O.O=C([O-])C(=O)CC1=CC=C(O)C=C1.O=C([O-])CC(=O)[O-].O=C([O-])CC1=C(O)C=CC(O)=C1 Chemical compound NC(CC1=CC=C(O)C=C1)C(=O)O.NC(CC1=CC=CC=C1)C(=O)O.O=C([O-])/C=C/C(=O)CC(=O)CC(=O)O.O=C([O-])/C=C/C(=O)[O-].O=C([O-])/C=C\C(=O)CC(=O)CC(=O)O.O=C([O-])C(=O)CC1=CC=C(O)C=C1.O=C([O-])CC(=O)[O-].O=C([O-])CC1=C(O)C=CC(O)=C1 FRUDQMSGWOBWDY-BKSNUZHZSA-H 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 201000010394 Ochronosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229920006130 high-performance polyamide Polymers 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940048333 nitisinone 2 mg Drugs 0.000 description 1
- 208000029347 ochronosis disease Diseases 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 229940039219 orfadin Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- KXFJZKUFXHWWAJ-UHFFFAOYSA-N p-hydroxybenzoylformic acid Natural products OC(=O)C(=O)C1=CC=C(O)C=C1 KXFJZKUFXHWWAJ-UHFFFAOYSA-N 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Definitions
- the invention relates to nitisinone (2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione) for use in the treatment of alkaptonuria, wherein nitisinone is administered in a dose of at least 4 mg per day.
- the invention also relates to a pharmaceutical composition comprising nitisinone for use in the treatment of alkaptonuria, wherein nitisinone is administered in a dose of at least 4 mg per day.
- Alkaptonuria is an autosomal recessive disorder caused by a deficiency of the enzyme homogentisate 1,2-dioxygenase (HGD). It is a rare disease affecting approximately one in every 250,000 to 1 million people. Due to the absence of HGD, alkaptonuria patients are unable to fully metabolize the amino acid tyrosine, which results in high plasma (or serum) levels of homogentisic acid (HGA). Despite efficient and marked urinary excretion of much of the HGA formed in AKU patients, some of it is oxidized to a melanin-like polymeric pigment via benzoquinone acetic acid (BQA).
- BQA benzoquinone acetic acid
- This pigment polymer is deposited in connective tissues (particularly cartilage) in a process termed ochronosis. This leads to severe arthritis of the spine and synovial joints with an early onset. Until the late 20s or early 30s, there are few clinical features aside from dark urine. Thereafter, progressive arthritic pain begins, affecting the spine and all synovial joints. The high levels of HGA further cause damage to heart valves and lead to the formation of kidney stones, as well as prostate stones in men.
- Nitisinone has been shown to reduce plasma/serum HGA levels and urinary excretion in patients with AKU (Phornphutkul et al., N. Engl. J. Med. 2002, vol. 347, no. 26, p.2111-2121; Suwannarat et al., Metabolism 2005, vol. 54, p.719-728; Introne et al., Mol. Genet. Metab. 2011, vol. 103, no. 4, p.307-314).
- Nitisinone (2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione) is a competitive inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPPD). Under the brand name Orfadin®, it is used in the treatment of hypertyrosinaemia type 1 (HT-1) where it acts by blocking the metabolic degradation of 4-hydroxyphenylpyruvate. Nitisinone thereby prevents the formation of HGA and the accumulation of the toxic intermediates maleylacetoacetate (MAA) and fumarylacetoacetate (FAA) in HT-1 patients (see scheme 1).
- MAA maleylacetoacetate
- FAA fumarylacetoacetate
- Nitisinone has also been investigated for the treatment of AKU in a long-term (36 months) clinical trial in a dose of 2 mg/day. Although the urinary excretion of nitisinone was reduced by about 95% on average, compared to pre-treatment levels, the trial failed to show an effect on the primary efficacy variable, hip rotation (Introne et al., Mol. Genet. Metab. 2011, vol. 103, no. 4, p. 307-314).
- FIG. 1 shows a plot of the urinary excretion of HGA at baseline and at week 4 for all patients (including untreated controls).
- FIG. 2 shows a plot of u-HGA 24 ( ⁇ mol) at week 4 for nitisinone-treated patients.
- FIG. 3 shows a plot of the daily average serum concentrations of tyrosine ( ⁇ mol/L) at baseline and week 4 for nitisinone-treated patients.
- FIG. 4 shows a plot of the urinary excretion of HGA and serum concentrations of tyrosine at week 4 for all patients (including untreated controls).
- FIG. 5 shows a plot of the urinary excretion of HGA and serum concentrations of tyrosine at week 4 for nitisinone-treated patients.
- FIG. 6 shows the relationship between average daily serum tyrosine concentrations and urinary excretion of HGA for nitisinone-treated patients (1-8 mg daily).
- nitisinone The inevitable consequence of treatment with nitisinone is the elevation of tyrosine levels. In the treatment of HT-1, it is therefore recommended that a more restricted tyrosine and phenylalanine diet should be implemented to keep plasma tyrosine levels below 500 ⁇ mol/L.
- tyrosine levels in untreated patients were approximately 60 ⁇ M, whereas the 20 patients on nitisinone 2 mg daily had tyrosine levels of 332-1528 ⁇ M, with an average of 800 ⁇ M (Introne et al., supra). Stable but variably increased plasma tyrosine concentrations were seen by 3-4 weeks post-nitisinone. It is thus difficult to keep the tyrosine concentrations at or below an acceptable level without diet restrictions.
- serum tyrosine levels are kept as low as possible.
- serum tyrosine levels are normally between about 40 and 90 ⁇ mol/L, and levels higher than 500 ⁇ mol/L should generally be avoided.
- serum tyrosine levels already are between 600 and 1000 ⁇ mol/L.
- nitisinone at considerably higher doses than previously used in the treatment of alkaptonuria may suppress the formation of HGA to more than 99%, while only marginally further increasing the tyrosine level in serum.
- the dose of nitisinone can be increased without an increased risk of for example tyrosine-related side-effects.
- the invention relates to nitisinone for use in the treatment of alkaptonuria, wherein nitisinone is administered in a dose of at least 4 mg per day.
- the daily dose of nitisinone as disclosed herein represents a fixed daily dose. This means that the dose is not adjusted based on e.g. body weight of the patient.
- a dose of at least 4 mg nitisinone per day thus represents the minimum level of a fixed daily amount of nitisinone administered to a patient.
- nitisinone is administered in a dose of at least 6 mg per day. In a more preferred embodiment, nitisinone is administered in a dose of at least 8 mg per day. In a yet more preferred embodiment, nitisinone is administered in a dose of at least 10 mg per day.
- nitisinone is administered in a dose of 8-12 mg per day. In a most preferred embodiment, nitisinone is administered in a dose of 10 mg per day.
- nitisinone In order to limit the risk of side effects, the dose of nitisinone should not exceed 15 mg per day. It can be estimated by extrapolation that such a dose should be sufficient to decrease u-HGA by about 99.9% in a majority of patients.
- nitisinone is administered in a dose of at least 4 and up to 15 mg per day.
- nitisinone is administered in a dose of at least 6 and up to 15 mg per day.
- nitisinone is administered in a dose of at least 8 and up to 15 mg per day.
- nitisinone is administered in a dose of at least 10 and up to 15 mg per day.
- the invention also relates to the use of nitisinone in the manufacture of a medicament for the treatment of alkaptonuria, wherein the nitisinone is administered in the doses described above.
- the invention also relates to a method of treating alkaptonuria, comprising administering nitisinone to a patient in need of such treatment in the doses described above.
- the invention relates to nitisinone for use in the treatment of alkaptonuria as disclosed herein, wherein nitisinone is administered as a pharmaceutical composition which comprises nitisinone in admixture with one or more pharmaceutically acceptable excipients.
- the invention relates to a pharmaceutical composition
- nitisinone for use in the treatment of alkaptonuria, wherein nitisinone is administered in a dose of at least 4 mg per day.
- nitisinone is administered in a dose of at least 6 mg per day.
- nitisinone is administered in a dose of at least 8 mg per day.
- nitisinone is administered in a dose of 8-12 mg per day, such as 10 mg per day.
- nitisinone is administered in a dose of at least 4 and up to 15 mg per day.
- nitisinone is administered in a dose of at least 6 and up to 15 mg per day. In yet another embodiment, nitisinone is administered in a dose of at least 8 and up to 15 mg per day. In yet another embodiment, nitisinone is administered in a dose of at least 10 and up to 15 mg per day.
- the pharmaceutical composition comprising nitisinone may additionally comprise one or more pharmaceutically acceptable excipients.
- the daily dose of nitisinone may be a single dose that is administered once a day, or may be divided into two or more smaller doses that are administered several times a day.
- the frequency of administration can remain constant or be variable during the duration of the treatment.
- nitisinone is administered once daily as a single dose.
- nitisinone is administered orally.
- Nitisinone can be administered in a composition comprising a therapeutically effective amount of the active ingredient, in admixture with one or more pharmaceutically acceptable excipients.
- a composition comprising nitisinone can be formulated as, e.g., capsules, tablets, solutions and oral dispersions.
- a suitable liquid pharmaceutical composition for oral administration is disclosed in WO 2012/177214. Said liquid pharmaceutical composition comprises a suspension of an effective amount of micronized nitisinone and citric acid buffer having a pH in the range of 2.5 to 3.5, preferably pH 3.0.
- a randomized, open-label, parallel-group dose-response study with a no-treatment control group was performed. Patients with AKU were randomized to receive either 1 mg, 2 mg, 4 mg or 8 mg nitisinone once daily (oral administration) or no treatment (control). Forty patients were randomized, equally distributed amongst the five groups (8 patients per group).
- Nitisinone was administered as an oral suspension containing 4 mg/mL. The following dose volumes were administered once daily, in the morning:
- Each dose was given to a group of 8 patients, and there was an untreated control group also consisting of 8 patients.
- Urinary excretion of HGA over a 24-hour period was assessed at weeks 0, 2 and 4. Urine was collected into 2.5-L bottles containing 30 mL of 5N H 2 SO 4 . The exact length of the collection interval and the volume of the collected urine were recorded. The concentration of HGA in the urine was measured by liquid chromatography tandem mass spectrometry (LCMSMS). The 24-hour excretion of HGA was calculated by multiplying the concentration with the volume of the collected urine, and correcting for any deviation from a 24-hour collection period. (There were no reports of missed samples within the collection interval.)
- the concentrations of HGA and tyrosine in the serum were measured by liquid chromatography tandem mass spectrometry (LCMSMS).
- the lower limit of quantification (LLOQ) for HGA was 3.1 ⁇ mol/L.
- FIG. 1 all patients, including the untreated control group
- FIG. 2 nitisinone-treated patients only.
- treatment with nitisinone led to a dose-dependent decrease in urinary excretion of HGA, and the inter-individual variability in the data also decreases with increasing doses.
- FIG. 3 shows the daily average serum concentrations of tyrosine ( ⁇ mol/L) at baseline and week 4 for all doses. It can be seen that the inter-individual variability in s-Tyr is of the same magnitude for all doses.
- the dose-response relationship for serum concentrations of tyrosine is less distinct than observed for u-HGA 24 .
- the inter-individual variability in s-Tyr is of the same magnitude for all doses.
- u-HGA 24 The relationship between u-HGA 24 and serum tyrosine is also illustrated in FIG. 6 .
- s-Tyr When u HGA 24 is above 2000 ⁇ mol, s-Tyr is in the range of 500 to 700 ⁇ mol/L.
- s-Tyr When u-HGA 24 is decreased to below 2000 ⁇ mol (i.e., for most patients on doses from 2 mg and upward), then s-Tyr is in the range of 600-1000 ⁇ mol/L but with no correlation between s-Tyr and u-HGA 24 .
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450521-8 | 2014-04-30 | ||
| SE1450521 | 2014-04-30 | ||
| PCT/EP2015/059352 WO2015165972A1 (en) | 2014-04-30 | 2015-04-29 | Nitisinone dosing regimens for the treatment of alkaptonuria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20170049716A1 true US20170049716A1 (en) | 2017-02-23 |
Family
ID=53175441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/307,622 Abandoned US20170049716A1 (en) | 2014-04-30 | 2015-04-29 | Nitisinone dosing regimens for the treatment of alkaptonuria |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170049716A1 (enExample) |
| EP (1) | EP3137066A1 (enExample) |
| JP (1) | JP2017514820A (enExample) |
| AU (1) | AU2015254669A1 (enExample) |
| BR (1) | BR112016024756A2 (enExample) |
| CA (1) | CA2947062A1 (enExample) |
| IL (1) | IL248506A0 (enExample) |
| MA (1) | MA39918A (enExample) |
| SG (1) | SG11201608957VA (enExample) |
| TN (1) | TN2016000479A1 (enExample) |
| WO (1) | WO2015165972A1 (enExample) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301932B2 (en) * | 2011-06-23 | 2016-04-05 | Swedish Orphan Biovitrum International Ab | Liquid pharmaceutical composition comprising nitisinone |
-
2015
- 2015-04-29 AU AU2015254669A patent/AU2015254669A1/en not_active Abandoned
- 2015-04-29 SG SG11201608957VA patent/SG11201608957VA/en unknown
- 2015-04-29 WO PCT/EP2015/059352 patent/WO2015165972A1/en not_active Ceased
- 2015-04-29 TN TN2016000479A patent/TN2016000479A1/en unknown
- 2015-04-29 BR BR112016024756A patent/BR112016024756A2/pt not_active IP Right Cessation
- 2015-04-29 JP JP2016564948A patent/JP2017514820A/ja active Pending
- 2015-04-29 MA MA039918A patent/MA39918A/fr unknown
- 2015-04-29 CA CA2947062A patent/CA2947062A1/en not_active Abandoned
- 2015-04-29 US US15/307,622 patent/US20170049716A1/en not_active Abandoned
- 2015-04-29 EP EP15722113.6A patent/EP3137066A1/en not_active Withdrawn
-
2016
- 2016-10-26 IL IL248506A patent/IL248506A0/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301932B2 (en) * | 2011-06-23 | 2016-04-05 | Swedish Orphan Biovitrum International Ab | Liquid pharmaceutical composition comprising nitisinone |
Non-Patent Citations (2)
| Title |
|---|
| Australian Public Assessment Report for Nitisinone 2011. * |
| Nelwan, Overcome Alkaptonuria, Journal of Biology, Agriculture and Healthcare Vol. 3, No. 10, 2013. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015165972A1 (en) | 2015-11-05 |
| IL248506A0 (en) | 2016-12-29 |
| AU2015254669A1 (en) | 2016-12-15 |
| JP2017514820A (ja) | 2017-06-08 |
| MA39918A (fr) | 2017-03-08 |
| TN2016000479A1 (en) | 2018-04-04 |
| SG11201608957VA (en) | 2016-11-29 |
| CA2947062A1 (en) | 2015-11-05 |
| BR112016024756A2 (pt) | 2017-08-15 |
| EP3137066A1 (en) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102547164B1 (ko) | 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 | |
| AU2011334617B2 (en) | Folic acid - Ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
| US20210008089A1 (en) | Compositions and methods for treating an aggregation disease or disorder | |
| US9592291B2 (en) | Methods for iontophoretically treating nausea and migraine | |
| US11679117B2 (en) | Ganaxolone for use in treatment of status epilepticus | |
| US20220347181A1 (en) | Agent for treating nocturnal pollakiuria | |
| US20170368059A1 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
| US10357453B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
| US20220288096A1 (en) | Compositions and methods for treating an aggregation disease or disorder | |
| US20170049716A1 (en) | Nitisinone dosing regimens for the treatment of alkaptonuria | |
| RU2369393C2 (ru) | Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна | |
| Ghimire et al. | Comparative efficacy of steroid nasal spray versus antihistamine nasal spray in allergic rhinitis | |
| US20240423961A1 (en) | 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones | |
| WO2013062441A1 (ru) | Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения | |
| Dewinter | The continuous search for new approaches improving postoperative outcomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OLSSON, BIRGITTA;REEL/FRAME:040705/0407 Effective date: 20161107 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |